Modern  ||| S:0 E:7 ||| JJ
diagnostic  ||| S:7 E:18 ||| JJ
approaches  ||| S:18 E:29 ||| NNS
to  ||| S:29 E:32 ||| TO
malignant  ||| S:32 E:42 ||| FW
hyperthermia  ||| S:42 E:55 ||| FW
susceptibility  ||| S:55 E:70 ||| FW
Malignant  ||| S:70 E:80 ||| FW
hyperthermia  ||| S:80 E:93 ||| FW
is  ||| S:93 E:96 ||| VBZ
a  ||| S:96 E:98 ||| DT
well-known  ||| S:98 E:109 ||| JJ
rare  ||| S:109 E:114 ||| JJ
life-threatening  ||| S:114 E:131 ||| JJ
autosomal-dominant  ||| S:131 E:150 ||| JJ
pharmacogenetic  ||| S:150 E:166 ||| JJ
disease ||| S:166 E:173 ||| NN
,  ||| S:173 E:175 ||| ,
The  ||| S:175 E:179 ||| DT
arti-  ||| S:179 E:185 ||| JJ
cle  ||| S:185 E:189 ||| JJ
deals  ||| S:189 E:195 ||| NNS
with  ||| S:195 E:200 ||| IN
a  ||| S:200 E:202 ||| DT
halothane-caffeine  ||| S:202 E:221 ||| JJ
contracture  ||| S:221 E:233 ||| JJ
test ||| S:233 E:237 ||| NN
.  ||| S:237 E:239 ||| .
The  ||| S:239 E:243 ||| DT
test  ||| S:243 E:248 ||| NN
is  ||| S:248 E:251 ||| VBZ
a  ||| S:251 E:253 ||| DT
model  ||| S:253 E:259 ||| NN
of  ||| S:259 E:262 ||| IN
muscle  ||| S:262 E:269 ||| NN
reaction  ||| S:269 E:278 ||| NN
to  ||| S:278 E:281 ||| TO
triggers  ||| S:281 E:290 ||| VB
in-vitro  ||| S:290 E:299 ||| JJ
and  ||| S:299 E:303 ||| CC
it  ||| S:303 E:306 ||| PRP
is  ||| S:306 E:309 ||| VBZ
the  ||| S:309 E:313 ||| DT
golden  ||| S:313 E:320 ||| JJ
standard  ||| S:320 E:329 ||| NN
for  ||| S:329 E:333 ||| IN
malignant  ||| S:333 E:343 ||| JJ
hyperthermia  ||| S:343 E:356 ||| JJ
susceptibility  ||| S:356 E:371 ||| NNS
( ||| S:371 E:372 ||| -LRB-
MHS ||| S:372 E:375 ||| NNP
)  ||| S:375 E:377 ||| -RRB-
diagnosis ||| S:377 E:386 ||| NN
.  ||| S:386 E:388 ||| .
Genetic  ||| S:388 E:396 ||| JJ
analysis  ||| S:396 E:405 ||| NN
is  ||| S:405 E:408 ||| VBZ
less  ||| S:408 E:413 ||| JJR
invasive ||| S:413 E:421 ||| NN
,  ||| S:421 E:423 ||| ,
but  ||| S:423 E:427 ||| CC
its  ||| S:427 E:431 ||| PRP$
sensitivity  ||| S:431 E:443 ||| NN
is  ||| S:443 E:446 ||| VBZ
significantly  ||| S:446 E:460 ||| RB
lower ||| S:460 E:465 ||| JJR
.  ||| S:465 E:467 ||| .
The  ||| S:467 E:471 ||| DT
review  ||| S:471 E:478 ||| NN
discusses  ||| S:478 E:488 ||| VBD
both  ||| S:488 E:493 ||| PDT
the  ||| S:493 E:497 ||| DT
methods  ||| S:497 E:505 ||| NNS
which  ||| S:505 E:511 ||| WDT
are  ||| S:511 E:515 ||| VBP
essential  ||| S:515 E:525 ||| JJ
to  ||| S:525 E:528 ||| TO
be  ||| S:528 E:531 ||| VB
completely  ||| S:531 E:542 ||| RB
reproduced  ||| S:542 E:553 ||| VBN
in  ||| S:553 E:556 ||| IN
Russia ||| S:556 E:562 ||| NNP
,  ||| S:562 E:564 ||| ,
and  ||| S:564 E:568 ||| CC
their  ||| S:568 E:574 ||| PRP$
role  ||| S:574 E:579 ||| NN
in  ||| S:579 E:582 ||| IN
modern  ||| S:582 E:589 ||| JJ
approach  ||| S:589 E:598 ||| NN
to  ||| S:598 E:601 ||| TO
MHS  ||| S:601 E:605 ||| NNP
diagnosis ||| S:605 E:614 ||| NN
.  ||| S:614 E:616 ||| .
